You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

How does the 30-day cost of Relvar for the treatment of asthma compare with other ICS/LABA combinations?

List price: ICS/LABA combinations for the treatment of asthma graph

Please note: Dose categories are as per the BTS/SIGN guideline[2]. This information is sensitive to price changes; the drug costs here are based on list prices and information for currently available asthma therapies were last updated in 07.07.2017[1].  Prescribing decisions should not be based on cost alone. You should refer to the SPC of each medicine for further information such as indications, contraindications, precautions and adverse events[3].

What potential cost savings could the Ellipta portfolio offer in your locality?

To discuss potential cost savings available in your locality, please contact us via the ‘HOC: on-Demand’.


Download the 30 day drug acquisition cost information for asthma medicines


  1. Monthly Index of Medical Specialities Online. Available at:
  2. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2016. Available at:
  3. Summary of Product Characteristics. Available at:  

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies